Lorena Lupinacci

机构：Hospital Italiano de Buenos Aires

发表论文 55 篇 · 总被引 4051 次 · h-index 13

代表论文

• Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 (2022 · Journal of Clinical Oncology · 被引 401)
• First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial (2021 · Journal of Thoracic Oncology · 被引 324)
• Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. (2024 · Journal of Clinical Oncology · 被引 62)
• Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations (2022 · European Journal of Cancer · 被引 55)
• Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden (2024 · Journal for ImmunoTherapy of Cancer · 被引 42)
• Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden (2022 · Cancer Research · 被引 26)